NXTC
NASDAQ HealthcareNextCure, Inc. - Common Stock
Biotechnology
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.
�� 市场数据
| 价格 | $6.17 |
|---|---|
| 成交量 | 4,203,196 |
| 市值 | 25.11M |
| 贝塔系数 | 1.420 |
| RSI（14日） | 84.6 超买 |
| 200日均线 | $9.57 |
| 50日均线 | $4.88 |
| 52周最高 | $15.74 |
| 52周最低 | $1.55 |
| Forward P/E | -0.87 |
| Price / Book | 0.83 |
🎯 投资策略评分
NXTC 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🎈 Over-Hyped (98/100) — 此策略 超买股票（潜在做空标的）.
评分最低的策略： 💰 Dividend Daddy (15/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 NXTC in your text
粘贴任何文章、记录或帖子 — 工具将提取 NXTC 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-07-16.